SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Micronized Colestipol Hydrochloride Tablets

Trade Name: COLESTID; LESTID
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product for the treatment of high cholesterol (hyperlipidemia).

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Signal Word: Not required
Hazard Statements: Non-hazardous in accordance with international standards for workplace safety.

Other Hazards No data available
Australian Hazard Classification (NOHSC): Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

COLESTID

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Colestipol Hydrochloride	37296-80-3	Not Listed	Not Listed	Not Listed	88
Colloidal silicon dioxide	7631-86-9	231-545-4	Not Listed	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Cellulose acetate phthalate	9004-38-0	Not Listed	Not Listed	Not Listed	*
Glycerol triacetate	102-76-1	203-051-9	Not Listed	Not Listed	*
Carnauba wax	8015-86-9	232-399-4	Not Listed	Not Listed	*
Povidone	9003-39-8	Not Listed	Not Listed	Not Listed	*
Hydroxypropyl methylcellulose	9004-65-3	Not Listed	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions:	Store as directed by product packaging.
Specific end use(s):	Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Colestipol Hydrochloride

Pfizer OEL TWA-8 Hr:	3000µg/m^3

Colloidal silicon dioxide

Australia TWA	2 mg/m^3
Austria OEL - MAKs	4 mg/m^3
	0.3 mg/m^3
Czech Republic OEL - TWA	0.1 mg/m^3
	4.0 mg/m^3
Estonia OEL - TWA	2 mg/m^3
Finland OEL - TWA	5 mg/m^3
Germany - TRGS 900 - TWAs	4 mg/m^3
Germany (DFG) - MAK	4 mg/m^3
Ireland OEL - TWAs	6 mg/m^3
	2.4 mg/m^3
Latvia OEL - TWA	1 mg/m^3

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
	Listed
Slovakia OEL - TWA	4.0 mg/m^3
Switzerland OEL -TWAs	4 mg/m^3
	0.3 mg/m^3

Magnesium stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m^3
Lithuania OEL - TWA	5 mg/m^3
Sweden OEL - TWAs	5 mg/m^3

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	**Color:**	Light yellow
Odor:	No data available.	**Odor Threshold:**	No data available.
Molecular Formula:	Mixture	**Molecular Weight:**	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)
Colestipol Hydrochloride
Predicted Log P -1.32
Povidone
No data available
Cellulose acetate phthalate
No data available
Carnauba wax
No data available
Glycerol triacetate
No data available
Hydroxypropyl methylcellulose
No data available
Colloidal silicon dioxide
No data available

9. PHYSICAL AND CHEMICAL PROPERTIES

Magnesium stearate
No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammablity:
- **Autoignition Temperature (Solid) (°C):** No data available
- **Flammability (Solids):** No data available
- **Flash Point (Liquid) (°C):** No data available
- **Upper Explosive Limits (Liquid) (% by Vol.):** No data available
- **Lower Explosive Limits (Liquid) (% by Vol.):** No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
- **Oxidizing Properties:** No data available
- **Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.
- **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers
- **Hazardous Decomposition Products:** No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: Not acutely toxic . Not expected to cause skin irritation (based on components) .
Known Clinical Effects: Adverse effects most commonly reported in clinical use include gastrointestinal disturbances, constipation, abdominal pain flatulence, heartburn, diarrhea, nausea, and vomiting.

Acute Toxicity: (Species, Route, End Point, Dose)

Colestipol Hydrochloride
Rat Oral LD50 >1000 mg/kg
Mouse Oral LD50 >1000 mg/kg
Rat Intraperitoneal LD50 >4000 mg/kg
Mouse Intraperitoneal LD50 >4000 mg/kg

Povidone
Rat Oral LD50 100 g/kg

Hydroxypropyl methylcellulose
Rat Oral LD50 > 10,000 mg/kg

Magnesium stearate

11. TOXICOLOGICAL INFORMATION

Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m^3

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Colestipol Hydrochloride
Eye Irritation Rabbit Mild
Skin Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Colestipol Hydrochloride
1 Month(s) Rat Oral 300 mg/kg/day NOAEL No effects at maximum dose
14 Day(s) Rabbit Oral 4000 mg/kg/day NOAEL No effects at maximum dose
1 Month(s) Dog Oral 3000 mg/kg/day LOAEL None identified
18 Month(s) Rat Oral 2000 mg/kg/day NOAEL No effects at maximum dose
1 Year(s) Dog Oral 500 mg/kg/day LOAEL None identified

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Colestipol Hydrochloride
Reproductive & Fertility Rat Oral 1000 mg/kg/day NOAEL No effects at maximum dose
Embryo / Fetal Development Rat Oral 1000 mg/kg/day NOAEL Not Teratogenic
Embryo / Fetal Development Rabbit Oral 1000 mg/kg/day NOAEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Colestipol Hydrochloride
Bacterial Mutagenicity (Ames) *Salmonella* , *E. coli* Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Colestipol Hydrochloride
18 Month(s) Rat Oral 2000 mg/kg/day NOAEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Povidone
IARC: Group 3 (Not Classifiable)

Colloidal silicon dioxide
IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential:
Partition Coefficient: (Method, pH, Endpoint, Value)
Colestipol Hydrochloride
Predicted Log P -1.32

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
None required
This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Colestipol Hydrochloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

15. REGULATORY INFORMATION

Cellulose acetate phthalate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Glycerol triacetate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	203-051-9

Carnauba wax

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-399-4

Colloidal silicon dioxide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-545-4

Povidone

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Magnesium stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

Hydroxypropyl methylcellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

16. OTHER INFORMATION

Data Sources:	Pfizer proprietary drug development information. Safety data sheets for individual ingredients.
Reasons for Revision:	Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information.
Revision date:	15-Apr-2015
	Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet